


PHARMACEUTICAL 2019



AGILE THERAPEUTICS INC Rank 153 of 363





PHARMACEUTICAL 2019



AGILE THERAPEUTICS INC Rank 153 of 363

The relative strengths and weaknesses of AGILE THERAPEUTICS INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of AGILE THERAPEUTICS INC compared to the market average is the variable Property and Equipment, increasing the Economic Capital Ratio by 247% points. The greatest weakness of AGILE THERAPEUTICS INC is the variable Net Income, reducing the Economic Capital Ratio by 80% points.

The company's Economic Capital Ratio, given in the ranking table, is 121%, being 84% points above the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	8,458
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	2,218
Liabilities, Non-Current	0
Other Assets	18
Other Compr. Net Income	0
Other Expenses	542
Other Liabilities	0
Other Net Income	-721
Other Revenues	0
Property and Equipment	13,916
Research and Development	9,777
Selling, General and Administrative Expense	8,739

Output Variable	Value in 1000 USD
Assets	22,392
Liabilities	2,218
Expenses	19,058
Revenues	0
Stockholders Equity	20,174
Net Income	-19,779
Comprehensive Net Income	-19,779
Economic Capital Ratio	121%

